Login to Your Account

Abivax shares surge as ABX-464 shows promise in draining HIV reservoirs

By Cormac Sheridan
Staff Writer

Tuesday, May 2, 2017

DUBLIN – Shares in Abivax SA surged by more than 175 percent during trading Tuesday on news that its HIV maturation inhibitor, ABX-464, may be able to reduce viral reservoirs in HIV-infected patients.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription